scholarly journals Landscape and clinical significance of long non‐coding RNAs involved in multiple myeloma expressed fusion transcripts

2021 ◽  
Author(s):  
Ane Amundarain ◽  
Luis V. Valcárcel ◽  
Raquel Ordoñez ◽  
Leire Garate ◽  
Estíbaliz Miranda ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Significance ◽  
Fusion Transcripts ◽  
Non Coding Rnas

Long non‐coding RNAs (CASC2 and TUG1) in hepatocellular carcinoma: Clinical significance

2019 ◽  
Vol 21 (9) ◽  
Author(s):  
Noha S. Refai ◽  
Manal L. Louka ◽  
Hany Y. Halim ◽  
Iman Montasser
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Significance ◽  
Non Coding Rnas

The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma

Inflammation ◽  
2014 ◽  
Vol 38 (2) ◽  
pp. 705-709 ◽  
Author(s):  
Ping Feng ◽  
Ruhong Yan ◽  
Xiaoli Dai ◽  
Xiaofang Xie ◽  
Huiyan Wen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Significance ◽  
Treg Cells

scholarly journals Clinical significance of telomerase activity in multiple myeloma

Cancer ◽  
2002 ◽  
Vol 94 (8) ◽  
pp. 2232-2238 ◽  
Author(s):  
Motoaki Shiratsuchi ◽  
Koichiro Muta ◽  
Yasunobu Abe ◽  
Seiichi Motomura ◽  
Fumihiro Taguchi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Significance ◽  
Telomerase Activity

Clinical Significance of Serum Osteopontin in Patients with Multiple Myeloma

2007 ◽  
Vol 27 (6) ◽  
pp. 400-405 ◽  
Author(s):  
So Young Kang ◽  
Jae Jin Lee ◽  
Woo In Lee
Keyword(s):  
Multiple Myeloma ◽  
Clinical Significance

scholarly journals CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3086-3086
Author(s):  
Ruyi Xu ◽  
Yi Li ◽  
Haimeng Yan ◽  
Xi Huang ◽  
He Huang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Rna Sequencing ◽  
Clinical Significance ◽  
Drug Induced ◽  
Stat3 Pathway ◽  
Catalytic Activities ◽  
Knock Down ◽  
Chemotherapy Drug ◽  
Ccl2 Expression ◽  
Induced Apoptosis

Background: Despite with the introduction of novel chemotherapy agents to multiple myeloma (MM), chemoresistance remains the major problem in clinical management. The interaction of MM cells with different cell components in the tumor microenvironment is important for tumor growth and chemoresistance, in which macrophages (Mφs) represent the prominent components. Mφs, who provide a favorable microenvironment for MM cells, protect them from drug-induced apoptosis. Mφs have great plasticity and can differentiate into different functional states according to microenvironmental signals. We previously found that the chemokine CCL2 is overexpressed in MM patients and CCL2 promoted Mφs'infiltration in the MM-BM microenvironment. The present study aims to further investigate the clinical significance of CCL2 and elucidate the mechanism how it participates in Mφs-mediated MM chemoresistance. Methods: Clinical significance of CCL2 were investigated by immunohistochemistry and Elisa. Flow cytometry, quantitative real-time PCR and Western blotting were conducted to evaluated the apoptosis of MM cells and Mφs' polarization. RNA sequencing was performed to determine the key molecular induced by CCL2 in Mφs. Genetically modified cells (e.g., exhibiting siRNA knockdown, generating deletion mutants through lentiviruses) were employed to evaluate the functional significance of MCPIP1. Proteome Profiler Human phosphor-kinase antibody array was used to determine the changes of protein phosphorylation in Mφs caused by CCL2. MM xenograft models were used to evaluated the role of CCL2 and MCPIP1 in vivo. Results: We found that CCL2 expression is tightly associated with MM patients' treatment status. When newly diagnosed patients received 4 courses of PCD combined therapy, CCL2 expression in their BM significantly decreased. MM cell lines and PBMCs barely expressed CCL2, while Mφs highly expressed CCL2. Mφs interacted with MM cells further upregulated their expression of CCL2. These increased CCL2 in the MM' BM microenvironment had little effect on MM cells' proliferation and their drug responses, but CCL2-treated Mφs were more effective at protecting MM cells from bortezomib- and melphalan- induced apoptosis. CCL2 could also effectively polarize Mφs toward M2-like Mφs, which possess a stronger ability to protect MM cells from chemotherapy drug-induced apoptosis. RNA sequencing revealed that CCL2 significantly induced the immunosuppressive molecular MCP-1-induced protein (MCPIP1) in Mφs and the result was verified both in mRNA and protein level. MM cells cocultured with MCPIP1-knock down Mφs were more sensitive to drug-induced apoptosis than those cocultured with control Mφs. Mφs transfected with D141N mutant MCPIP1 lost their protective effects because the mutation resulted in impaired RNase and DUB activities of MCPIP1. Mφs isolated from NSG mice' tumor masses showed MCPIP1-knock down Mφs displayed a more M1-like phenotype and in vitro experiments showed MCPIP1-knock down Mφs were more difficult to be polarized toward M2-like Mφs by MM cells. CCL2 significantly activated JAK2/STAT3 pathway in Mφs and inhibition of STAT3 hindered CCL2-induced MCPIP1 protein expression. Conclusion: Our study showed that increased CCL2 in MM' BM microenvironment polarizes Mφs towards M2-like phenotype and promotes Mφs to protect MM cells from chemotherapy drug-induced apoptosis. Mechanistically, CCL2 activated JAK2/STAT3 pathway to induce the expression of MCPIP1. MCPIP1, the critical negative regulator of inflammation, mediated Mφs 'polarization and protection effect via its dual catalytic activities. Key words: Multiple Myeloma, Macrophages-Associated Chemoresistance, Polarization, CCL2, MCPIP1 Disclosures No relevant conflicts of interest to declare.

B cell-activating factor: its clinical significance in multiple myeloma patients

2012 ◽  
Vol 91 (9) ◽  
pp. 1413-1418 ◽  
Author(s):  
M. Fragioudaki ◽  
A. Boula ◽  
G. Tsirakis ◽  
F. Psarakis ◽  
M. Spanoudakis ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Clinical Significance ◽  
B Cell Activating Factor

scholarly journals MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance

2020 ◽  
Vol 21 (9) ◽  
pp. 3084 ◽  
Author(s):  
Vanessa Desantis ◽  
Ilaria Saltarella ◽  
Aurelia Lamanuzzi ◽  
Assunta Melaccio ◽  
Antonio Giovanni Solimando ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Drug Resistance ◽  
Cancer Progression ◽  
Tumor Suppressors ◽  
Therapeutic Approach ◽  
Physical Stability ◽  
Cellular Processes ◽  
Non Coding Rnas ◽  
Potential Use ◽  
Nuclease Degradation

MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation in the pathogenesis of multiple myeloma (MM), and discuss the potential use of miRs/nanocarriers association in clinic. Since miRs can act as oncogenes or tumor suppressors, strategies based on their inhibition and/or replacement represent the new opportunities in cancer therapy. The miRs delivery systems include liposomes, polymers, and exosomes that increase their physical stability and prevent nuclease degradation. Phase I/II clinical trials support the importance of miRs as an innovative therapeutic approach in nanomedicine to prevent cancer progression and drug resistance. Results in clinical practice are promising.

scholarly journals Long Non-Coding RNAs in Multiple Myeloma

2019 ◽  
Vol 5 (1) ◽  
pp. 13 ◽  
Author(s):  
Romana Butova ◽  
Petra Vychytilova-Faltejskova ◽  
Adela Souckova ◽  
Sabina Sevcikova ◽  
Roman Hajek
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Current Knowledge ◽  
Biological Processes ◽  
Cell Distribution ◽  
Rna Molecules ◽  
Non Coding Rna ◽  
Non Coding Rnas ◽  
New Treatment ◽  
Long Non Coding Rna

Multiple myeloma (MM) is the second most common hematooncological disease of malignant plasma cells in the bone marrow. While new treatment brought unprecedented increase of survival of patients, MM pathogenesis is yet to be clarified. Increasing evidence of expression of long non-coding RNA molecules (lncRNA) linked to development and progression of many tumors suggested their important role in tumorigenesis. To date, over 15,000 lncRNA molecules characterized by diversity of function and specificity of cell distribution were identified in the human genome. Due to their involvement in proliferation, apoptosis, metabolism, and differentiation, they have a key role in the biological processes and pathogenesis of many diseases, including MM. This review summarizes current knowledge of non-coding RNAs (ncRNA), especially lncRNAs, and their role in MM pathogenesis. Undeniable involvement of lncRNAs in MM development suggests their potential as biomarkers.

Clinical significance of circulating endothelial adhesion molecules (sE-selectin and sICAM) in untreated multiple myeloma patients

2004 ◽  
Vol 349 (1-2) ◽  
pp. 39-43 ◽  
Author(s):  
Michael G. Alexandrakis ◽  
Freda H. Passam ◽  
Katerina Sfiridaki ◽  
Panayiotis Kafarakis ◽  
Elli Karydi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adhesion Molecules ◽  
Clinical Significance ◽  
Endothelial Adhesion Molecules
Sign in / Sign up

Export Citation Format

Share Document